MARKET

MESO

MESO

Mesoblast
NASDAQ
2.070
+0.022
+1.07%
Closed 16:00 02/27 EST
OPEN
2.050
PREV CLOSE
2.048
HIGH
2.090
LOW
2.000
VOLUME
96.65K
TURNOVER
0
52 WEEK HIGH
10.24
52 WEEK LOW
1.610
MARKET CAP
168.54M
P/E (TTM)
-0.9341
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MESO last week (0219-0223)?
Weekly Report · 2d ago
Mesoblast Financial Results and Corporate Update Webcast
Barchart · 2d ago
Mesoblast Limited - Depositary Receipt () (MESO) Price Target Increased by 16.88% to 2.31
NASDAQ · 3d ago
Weekly Report: what happened at MESO last week (0212-0216)?
Weekly Report · 02/19 09:04
Mesoblast gets FDA orphan drug status for Revascor
Healthcare Mesoblast gets FDA orphan drug status for Revascor in the treatment of children with hypoplastic left heart syndrome. The cell therapy received rare pediatric disease designation from the FDA last month. Mesob last said the FDA has granted orphan drug designation to its cell therapy revascor.
Seeking Alpha · 02/15 16:54
Weekly Report: what happened at MESO last week (0205-0209)?
Weekly Report · 02/12 09:04
Weekly Report: what happened at MESO last week (0129-0202)?
Weekly Report · 02/05 09:04
Mesoblast Announces Advancements In Phase 3 Trials iIQ2 Activity Report, Registers $1.5M in Royalty Revenue From TEMCELL® HS Inj.5 Sales In Japan
Mesoblast announces results for the quarter ended December 31, 2023. Cash balance at the end of the quarter was A$113.4 million. Rare Pediatric Disease Designation from FDA for lead product Ryoncil for children with acute GVHD. Cost containment strategy on-track.
Benzinga · 01/31 07:10
More
About MESO
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.